ASH 2018 | Predictors of expansion/response to anti-BCMA CAR T-cells in R/R multiple myeloma

Adam Cohen

Adam Cohen, MD, of the University of Pennsylvania, Philadelphia, PA, discusses predictors of expansion and response following BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma. This expansion and response was correlated with a normal CD4:CD8 ratio and increased frequency of CD8+ T-cells with a CD45RO/CD27 phenotype, and not with tumor burden or other clinical characteristics. This has a number of implications for patient selection, timing of T-cell collection, and manufacturing processes. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video